Literature DB >> 19748399

Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates.

James P Watt1, Lara J Wolfson, Katherine L O'Brien, Emily Henkle, Maria Deloria-Knoll, Natalie McCall, Ellen Lee, Orin S Levine, Rana Hajjeh, Kim Mulholland, Thomas Cherian.   

Abstract

BACKGROUND: Haemophilus influenzae type b (Hib) is a leading cause of childhood bacterial meningitis, pneumonia, and other serious infections. Hib disease can be almost completely eliminated through routine vaccination. We assessed the global burden of disease to help national policy makers and international donors set priorities.
METHODS: We did a comprehensive literature search of studies of Hib disease incidence, case-fatality ratios, age distribution, syndrome distribution, and effect of Hib vaccine. We used vaccine trial data to estimate the proportion of pneumonia cases and pneumonia deaths caused by Hib. We applied these proportions to WHO country-specific estimates of pneumonia cases and deaths to estimate Hib pneumonia burden. We used data from surveillance studies to develop estimates of incidence and mortality of Hib meningitis and serious non-pneumonia, non-meningitis disease. If available, high-quality data were used for national estimates of Hib meningitis and non-pneumonia, non-meningitis disease burden. Otherwise, estimates were based on data from other countries matched as closely as possible for geographic region and child mortality. Estimates were adjusted for HIV prevalence and access to care. Disease burden was estimated for the year 2000 in children younger than 5 years.
FINDINGS: We calculated that Hib caused about 8.13 million serious illnesses worldwide in 2000 (uncertainty range 7.33-13.2 million). We estimated that Hib caused 371,000 deaths (247,000-527,000) in children aged 1-59 months, of which 8100 (5600-10,000) were in HIV-positive and 363,000 (242,000-517,000) in HIV-negative children.
INTERPRETATION: Global burden of Hib disease is substantial and almost entirely vaccine preventable. Expanded use of Hib vaccine could reduce childhood pneumonia and meningitis, and decrease child mortality. FUNDING: GAVI Alliance and the Vaccine Fund.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748399     DOI: 10.1016/S0140-6736(09)61203-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  176 in total

1.  Haemophilus influenzae type b carriage and novel bacterial population structure among children in urban Kathmandu, Nepal.

Authors:  E J Williams; J Lewis; T John; J C Hoe; L Yu; S Dongol; D F Kelly; D T Griffiths; A Shah; B Limbu; R Pradhan; F Mawas; S Shrestha; S Thorson; A M Werno; D R Murdoch; N Adhikari; A J Pollard
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  Integrating pneumonia prevention and treatment interventions with immunization services in resource-poor countries.

Authors:  Adam L Cohen; Terri B Hyde; Jennifer Verani; Margaret Watkins
Journal:  Bull World Health Organ       Date:  2012-04-01       Impact factor: 9.408

Review 3.  DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

4.  Pneumonia's second wind? A case study of the global health network for childhood pneumonia.

Authors:  David Berlan
Journal:  Health Policy Plan       Date:  2015-10-05       Impact factor: 3.344

5.  Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.

Authors:  Jian-li Hu; Hong Tao; Jing-xin Li; Wei-ming Dai; Bin Song; Jin-fang Sun; Pei Liu; Jie Tang; Wen-yu Liu; Shi-yuan Wang; Feng-cai Zhu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants.

Authors:  Ulla Kou Griffiths; Andrew Clark; Rana Hajjeh
Journal:  J Pediatr       Date:  2013-07       Impact factor: 4.406

7.  Pentavalent vaccine: a major breakthrough in India's Universal Immunization Program.

Authors:  Mohan Bairwa; Manju Pilania; Meena Rajput; Pardeep Khanna; Neelam Kumar; Mukesh Nagar; Sumit Chawla
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

8.  A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine.

Authors:  Shashank Dalvi; Prasad S Kulkarni; M A Phadke; S S More; Sanjay K Lalwani; Dipty Jain; Mamta Manglani; B S Garg; Mohan K Doibale; C T Deshmukh
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Closing the GAPP on pneumonia.

Authors: 
Journal:  Nat Rev Microbiol       Date:  2009-12       Impact factor: 60.633

10.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.